vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of “Moderate Buy” by Brokerages

Posted by on Sep 12th, 2026

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the nine research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $55.8333.

A number of analysts have recently weighed in on VTVT shares. Wall Street Zen lowered shares of vTv Therapeutics from a “buy” rating to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright reduced their target price on shares of vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, September 7th. Weiss Ratings downgraded shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Finally, BTIG Research boosted their price objective on shares of vTv Therapeutics from $49.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, July 16th.

Get Our Latest Analysis on vTv Therapeutics

Institutional Trading of vTv Therapeutics

Hedge funds have recently made changes to their positions in the business. 683 Capital Management LLC purchased a new stake in shares of vTv Therapeutics during the fourth quarter worth $731,000. Geode Capital Management LLC grew its stake in vTv Therapeutics by 84.3% during the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new position in vTv Therapeutics during the 4th quarter worth $221,000. Institutional investors and hedge funds own 17.51% of the company’s stock.

vTv Therapeutics Trading Up 0.3%

Shares of VTVT stock opened at $31.97 on Friday. The business’s fifty day simple moving average is $32.69 and its 200-day simple moving average is $34.46. vTv Therapeutics has a 12-month low of $18.97 and a 12-month high of $44.00. The company has a market cap of $125.96 million, a PE ratio of -30.16 and a beta of 0.29.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.08). On average, equities analysts forecast that vTv Therapeutics will post -2.35 earnings per share for the current year.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.

Featured Articles

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.